Lowest-Rated StocksLowest-RatedNASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Price, News & Analysis $17.52 +0.42 (+2.43%) As of 10:35 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Sarepta Therapeutics Stock (NASDAQ:SRPT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sarepta Therapeutics alerts:Sign Up Key Stats Today's Range$17.12▼$17.7850-Day Range$16.51▼$23.2152-Week Range$14.68▼$24.68Volume249,406 shsAverage Volume3.09 million shsMarket Capitalization$1.85 billionP/E RatioN/ADividend YieldN/APrice Target$22.59Consensus RatingReduce Company Overview Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs include RNA-based therapies, gene therapy and other genetic medicine approaches designed to address the underlying causes of serious genetic disorders. The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for certain patients with DMD mutations, as well as Elevidys, a gene therapy for eligible patients with Duchenne muscular dystrophy. The availability and approved uses of these products may vary by jurisdiction and patient population. Sarepta was originally established as AntiVirals and later operated as AVI BioPharma before adopting the Sarepta Therapeutics name in 2012. Headquartered in Cambridge, Massachusetts, the company conducts research and commercial activities in the United States and serves patients and healthcare providers through its therapies and related support programs, while continuing to develop treatments for additional rare genetic diseases.AI Generated. May Contain Errors. Read More Sarepta Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreSRPT MarketRank™: 3.53304140127 of 5 starsSarepta Therapeutics scored higher than 71% of companies evaluated by MarketBeat, and ranked 213th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingReduce Consensus RatingSarepta Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.95, and is based on no strong buy ratings, 7 buy ratings, 6 hold ratings, and 8 sell ratings.Upside PotentialSarepta Therapeutics has a consensus price target of $22.59, representing about 32.1% upside from its current price of $17.10.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sarepta Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-59.02% Earnings GrowthEarnings for Sarepta Therapeutics are expected to decrease by -59.02% in the coming year, from $3.27 to $1.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioSarepta Therapeutics has a PEG Ratio of 0.31. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sarepta Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted23.17% of the float of Sarepta Therapeutics has been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 8.62.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 10.42%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.56 News SentimentSarepta Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Sarepta Therapeutics this week, compared to 8 articles on an average week.Search InterestOnly 5 people have searched for SRPT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows5 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.90% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sarepta Therapeutics' insider trading history. Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SRPT Stock News HeadlinesCartesian Therapeutics (NASDAQ:RNAC) and Sarepta Therapeutics (NASDAQ:SRPT) Head to Head ContrastOctober 19 at 4:28 AM | americanbankingnews.comLeerink Partners Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)October 16 at 7:38 PM | theglobeandmail.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 19 at 1:00 AM | Stansberry Research (Ad)Sarepta Therapeutics Faces New Growth Opportunity Emerging From SiRNA Programs, Wedbush SaysOctober 16 at 2:37 PM | finance.yahoo.comSarepta Therapeutics: Buy Rating Reiterated on Expanding RNA Pipeline; Price Target Maintained at $35October 16 at 8:10 AM | tipranks.comSarepta Therapeutics, Inc. Presents New Preclinical Data Demonstrating Robust Knockdown Of Pathogenic DMPK RNA In The Nucleus With SRP-1003 In DM1 At 2026 Oligonucleotide ...October 15, 2026 | marketscreener.comMSarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide ...October 15, 2026 | marketscreener.comMSarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual MeetingOctober 14, 2026 | finance.yahoo.comSee More Headlines SRPT Stock Analysis - Frequently Asked Questions How have SRPT shares performed this year? Sarepta Therapeutics' stock was trading at $21.52 at the start of the year. Since then, SRPT stock has decreased by 20.5% and is now trading at $17.10. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) posted its quarterly earnings results on Wednesday, August, 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.42. The firm's revenue for the quarter was down 34.3% compared to the same quarter last year. Read the conference call transcript. Does Sarepta Therapeutics have any subsidiaries? The following companies are subsidiaries of Sarepta Therapeutics: Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc.. Who are Sarepta Therapeutics' major shareholders? Top institutional shareholders of Sarepta Therapeutics include State of Alaska Department of Revenue (0.02%). Insiders that own company stock include Douglas S Ingram, Michael Andrew Chambers, Ian Michael Estepan, Richard Barry, Claude Nicaise, Hans Lennart Rudolf Wigzell, Bilal Arif, Dallan Murray, Ryan Edward Brown, Kathryn Jean Boor and Stephen Mayo. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), Netflix (NFLX) and Gilead Sciences (GILD). Company Calendar Last Earnings8/05/2026Today10/19/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, SRPT's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CIK873303 Webwww.sarepta.com Phone(617) 274-4000Fax425-354-5038Employees835Year Founded1980Price Target and Rating Average Price Target for Sarepta Therapeutics$22.59 High Price Target$38.00 Low Price Target$5.00 Potential Upside/Downside+28.3%Consensus RatingReduce Rating Score (0-4)1.95 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($2.90) Trailing P/E RatioN/A Forward P/E Ratio5.39 P/E Growth0.31Net Income-$713.41 million Net Margins-13.48% Pretax Margin-6.63% Return on Equity-1.60% Return on Assets-0.66% Debt Debt-to-Equity Ratio0.55 Current Ratio4.42 Quick Ratio2.62 Sales & Book Value Annual Sales$1.97 billion Price / Sales0.94 Cash FlowN/A Price / Cash FlowN/A Book Value$10.89 per share Price / Book1.62Miscellaneous Outstanding Shares105,627,000Free Float98,339,000Market Cap$1.86 billion OptionableOptionable Beta0.38 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:SRPT) was last updated on 10/19/2026 by MarketBeat.com Staff. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
